Summary
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
History
Founded in 2018 by world-renowned scientists and entrepreneurs, Sana Biotechnology is a privately held company based out of Seattle, Washington. With more than a decade of experience in the fields of stem cell therapeutics and gene editing, the founding team of Sana Biotechnology has already made a signature contribution to the development of various new cell therapies.
Mission
Our mission is to empower patients’ own cells to become the medicine needed to create life-changing and eventually curative treatments for serious diseases.
Vision
Our vision is to revolutionize medicine and expand access to life-changing cures for patients by leveraging stem cells and gene editing.
Key Team
Dr. Sunil Agarwal M.D. (Exec. VP, Head of Devel. & Chief Medical Officer)
Brittany Mccleery (Accounting Mang.)
Dr. Edward Rebar Ph.D. (Sr. VP & CTO)
Mr. Bernard J. Cassidy J.D. (Exec. VP & Gen. Counsel)
Ms. Robin Andrulevich (Exec. VP & Chief People Officer)
Mr. Paul Brunetta M.D. (Sr. VP and Head of Clinical & Translational Science)
Ms. Donna Dambach D.V.M., Ph.D. (Sr. VP & Head of Devel. Sciences)
Recognition and Awards
Sana Biotechnology has won numerous awards and accolades, including being named one of the top 100 most innovative private companies in the world and being selected as one of the Top 10 Healthcare Startups to watch by Forbes.
References
United States 
